title: Linagliptin use in older individuals with type 2 diabetes.
abstract: Older people have the highest prevalence of type 2 diabetes mellitus (T2DM) of any age group and are thus frequent users of glucose-lowering agents. Because individuals 65 years or older are underrepresented in clinical studies, there is a lack of information regarding the efficacy and safety of available treatments in this population. Additionally, a high prevalence of comorbidities, polypharmacy, and frailty can make treatment of T2DM in this population challenging. Safety is an important consideration when choosing a treatment for older individuals. Renal impairment is quite common in older patients with T2DM and can contribute to hypoglycemia. Hypoglycemia can lead to serious consequences, such as falls and fractures, and cognitive changes. As such, hemoglobin A₁c treatment targets, typically <7% in the general population, are less stringent in older people, with the goal being an individualized target that balances efficacy and safety. Many glucose-lowering agents can cause adverse events detrimental to older individuals, such as hypoglycemia (insulin, sulfonylureas), weight gain (sulfonylureas, thiazolidinediones), gastrointestinal events (metformin), and fractures (thiazolidinediones), and are contraindicated or require dose adjustments in those with renal impairment (most oral/injectable agents). Orally administered dipeptidyl peptidase (DPP)-4 inhibitors have a low risk of hypoglycemia and are generally well tolerated. Linagliptin is the only DPP-4 inhibitor excreted through nonrenal pathways and therefore does not require any dose adjustment in older patients with kidney disease. This paper reviews the findings of a recent study by Barnett et al assessing the efficacy and safety of the DPP-4 inhibitor linagliptin in patients with T2DM aged 70 years or older, which concluded that linagliptin may be a useful glucose-lowering option for older patients with T2DM.
authors.affiliation: Florida Hospital Diabetes Institute, Orlando, FL, USA ; Translational Research Institute for Metabolism and Diabetes, Orlando, FL, USA ; Sanford-Burnham Medical Research Institute, Orlando, FL, USA.
authors.forename: Richard E
authors.initials: RE
authors.lastname: Pratley
mesh_terms: D000368:Aged; D000375:Aging; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069476:Linagliptin; D011687:Purines / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011687:Purines; D011799:Quinazolines; D000069476:Linagliptin
keywords: DPP-4 inhibitors; clinical trial; hypoglycemia; renal impairment
references.citation: Diabetes Care. 2007 Dec;30(12):3017-22
references.pmid: 17878242
references.citation: J Am Geriatr Soc. 2012 Dec;60(12):2342-56
references.pmid: 23106132
references.citation: Curr Med Res Opin. 2011 May;27(5):1049-58
references.pmid: 21428727
references.citation: Am J Geriatr Pharmacother. 2011 Dec;9(6):423-33
references.pmid: 22055210
references.citation: Diabetes Obes Metab. 2009 Aug;11(8):804-12
references.pmid: 19476473
references.citation: Nutr Metab Cardiovasc Dis. 2010 May;20(4):224-35
references.pmid: 19515542
references.citation: J Am Geriatr Soc. 2009 Nov;57(11):2011-9
references.pmid: 19793357
references.citation: Diabetes Care. 2012 Dec;35(12):2650-64
references.pmid: 23100048
references.citation: Diabetologia. 2013 Jun;56(6):1226-35
references.pmid: 23564296
references.citation: Diabetes Care. 2013 Jan;36 Suppl 1:S11-66
references.pmid: 23264422
references.citation: Curr Med Res Opin. 2011 Apr;27(4):863-9
references.pmid: 21323504
references.citation: Vital Health Stat 10. 2010 Dec;(249):1-207
references.pmid: 21905346
references.citation: Diabetes Obes Metab. 2013 Oct;15(10):906-14
references.pmid: 23531118
references.citation: Clin Interv Aging. 2013;8:419-30
references.pmid: 23626461
references.citation: Am J Geriatr Pharmacother. 2010 Oct;8(5):405-18
references.pmid: 21335294
references.citation: Lancet. 2013 Aug 3;382(9890):409-416
references.pmid: 23706759
references.citation: Lancet. 2013 Oct 26;382(9902):1413-23
references.pmid: 23948125
references.citation: Clin Ther. 2011 Dec;33(12):1868-82
references.pmid: 22136979